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ABBREVIATIONS
AP(d)  action potential (duration) 
Ca2+   calcium ion 
cAMP  cyclic adenosine monophosphate 
EAD  early afterdepolarization 
ECG  electrocardiogram 
HR  heart rate 
ICa   cardiac calcium current 
IK   delayed rectifier potassium current 
IKs    fast component of the delayed rectifier potassium current 
IKs    slow component of the delayed rectifier potassium current  
INa  cardiac sodium current 
K+  potassium ion 
KCNH2/KCNH2 voltage-gated potassium channel ?-subunit (gene/protein) 
KCNE1/KCNE1  voltage-gated potassium channel ?-subunit (gene/protein) 
KCNE2/KCNE2   voltage-gated potassium channel ?-subunit (gene/protein) 
KCNQ1/KCNQ1 voltage-gated potassium channel ?-subunit (gene/protein) 
LQTS  long QT syndrome 
MAP(d)   monophasic action potential (duration)
M-cell  mid-myocardial cell 
Na+  sodium ion 
PCR   polymerase chain reaction 
PKA  protein kinase A 
PKC   protein kinase C 
QTc   QT-interval adjusted to heart rate according to Bazett 
QTfc   QT-interval adjusted to heart rate according to Fridericia 
RR  RR interval on the ECG 
SCN5A/SCN5A voltage-gated sodium channel ?-subunit (gene/protein) 
SEVC   single electrode voltage clamp  
VF  ventricular fibrillation 
VT  ventricular tachycardia 
WT   wild type 
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ABSTRACT
Long QT syndrome is a congenital or acquired arrhythmic disorder which manifests as a 
prolonged QT-interval on the electrocardiogram and as a tendency to develop ventricular 
arrhythmias which can lead to sudden death. Arrhythmias occur during intense exercise and/or 
emotional stress. The two most common subtypes of LQTS are LQT1, caused by mutations in 
the KCNQ1 gene and LQT2, caused by mutations in the KCNH2 gene. LQT1 and LQT2 
patients exhibit arrhythmias in different types of situations: in LQT1 the trigger is usually 
vigorous exercise whereas in LQT2 arrhythmia results by the patient being startled from rest.
It is not clear why trigger factors and clinical outcome differ from each other in the different 
LQTS subtypes. It is possible that stress hormones such as catecholamines may show different 
effects depending on the exact nature of the genetic defect, or sensitivity to catecholamines 
varies from subject to subject. Furthermore, it is possible that subtle genetic variants of 
putative modifier genes, including those coding for ion channels and hormone receptors, play a 
role as determinants of individual sensitivity to life-threatening arrhythmias. The present study 
was designed to identify some of these risk modifiers. Therefore, in vivo studies using systems 
to induce mental and physical stress as well as in vitro studies on genetic polymorphism of 
candidate genes were designed.
During mental stress validated by hemodynamic and cathecolaminergic responses, the mean 
QT-interval shortened to a similar extent in controls (-29 ms), LQT1 patients (-34 ms) and 
LQT2 patients (-30 ms). During exercise, the corresponding QT-adaptation was more 
pronounced in healthy controls (-47 ms) than in LQT1 (-38 ms) or LQT2 patients (-38 ms). 
Thus, LQT1 and LQT2 patients could not be differentiated from one another on the basis of 
QT-adaptation to mental stress.   
During rapid right atrial pacing at progressively shorter diastolic intervals, LQT1 and LQT2 
could be differentiated because LQT1 patients had different action potential restitution kinetics 
during epinephrine infusion. Furthermore, the monophasic action potential shape measured 
from the right atrium was different in LQT1 and LQT2. In LQT1, the monophasic action 
potential shape was less triangular at baseline than in LQT2, during epinephrine infusion, it 
became more triangular. Action potential triangulation is considered to predispose to 
ventricular arrhythmia. Therefore, these findings may explain, at least in part, the propensity of 
LQT1 patients to develop ventricular arrhythmia during intense sympathetic activation. 
In vitro electrophysiological as well as clinical studies were performed to find out whether the 
most common KCNH2 polymorphism in Finland, K897T, influences channel function or 
phenotype. Maximal current of the K897 channel was larger in transiently transfected 
mammalian cells then the T897 channel due to increased channel expression. In a maximal 
exercise test in 39 patients carrying an identical KCNQ1 mutation and showing a prolonged 
QT-interval, QT-intervals were longer in patients carrying the T897 allele than in those 
homozygous for the K897 allele. It remains to be seen whether this polymorphism is a 
clinically significant risk factor for symptomaticity in larger LQTS populations. 
To study the role of ?1-adrenergic receptor variations as LQTS modifier genes clinical data 
and DNA samples from 168 LQT1 patients were analyzed. A common ?-adrenergic receptor 
polymorphism (R389G) was found to alter QT-interval and that compound homozygosity for 
two ?-adrenergic receptor polymorphisms (R389G and S49G) increased risk of arrhythmia in 
LQT1 patients. Patients with the R389 genotype have shorter QT-intervals at rest and during 
exercise than patients with the R389G and G389 genotypes.
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In summary, the present findings show that, as compared to nonaffected controls, patients with 
long QT syndrome show an abnormal QT-adaptation to both physical and mental stress. As 
studied with epinephrine infusion experiments, LQT1 patients with the KCNQ1 mutations 
show repolarization abnormalities which may be related to their propensity to develop 
arrhythmias during increased sympathetic activity. A common KCNH2 polymorphism was 
show to affect KCNH2 channel function as well as QT dynamics in vivo, although its exact 
clinical significance warrants further study. Finally, the present study also identifies a common 
?1-adrenergic receptor genotype that is related to occurrence of symptoms in LQT1 type of 
long QT syndrome.  
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1. INTRODUCTION 
The long QT syndrome is a an inherited or acquired channelopathy predisposing to arrhythmia 
and sudden death. The inherited form is divided into subgroups as determined by the type of 
malfunctioning channel protein. This type of LQTS may be caused by mutations in the 
potassium channel ?-subunit genes KCNQ1 (LQT1), KCNH2 (LQT2), the sodium channel 
gene SCN5A (LQT3), the ankyrin gene (LQT4), the potassium channel ?-subunit genes 
KCNE1 (LQT5) and KCNE2 (LQT6), or the potassium channel gene KCNJ2 (LQT7). Even 
though this disease is not overly prevalent in the general population; it is fatal in up to 50% of 
the individuals it afflicts if left untreated. LQT1 and LQT2 are the most common types of 
congenital LQTS in Finland, accounting for over 70% of the disease.  
The clinical picture of LQTS varies according to its subtype. LQT1 is characterized by 
arrhythmia as a result of strenuous exercise such as swimming, whereas in LQT2 arrhythmia 
occurs most often at rest as a result of a sudden increase of adrenergic tone without physical 
stress, for example when the patient is awakened from sleep by an alarm clock. In the acquired 
form of LQTS, arrhythmia is caused by drugs that block ion channels responsible for the rapid 
delayed rectifier current IKr in the heart.  
A major open question is why in families where individuals carry the same LQTS-causing 
mutation some develop arrhythmia and others do not. The aim of the present study was to 
explore differences between electrophysiological characteristics of LQT1 and LQT2 patients 
and to determine whether additional factors such as ion-channel polymorphisms or 
polymorphisms in other genes controlling potassium channel function could increase the basal 
risk of arrhythmia. 
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2. REVIEW OF THE LITERATURE 
2.1 History of LQTS 
The inherited long QT syndrome (LQTS) is a myocardial ion channel disease characterized by 
prolongation of the QT-interval in the electrocardiogram (ECG) and associated with a 
predisposition to ventricular arrhythmias manifested as fainting spells and sudden death. A 
specific type of cardiac ventricular tachycardia called torsade des pointes causes cardiogenic 
syncope in LQTS. 
Already 2400 years ago Hippocrates, the ancient Greek physician, stated that people 
experiencing repeated fainting spells are likely to die suddenly at a young age (Jones 1924). 
Hippocrates may have collected observations on patients with LQTS, the Brugada syndrome, 
arrhythmogenic right ventricular dysplasia, hypertrophic cardiomyopathy or some other form 
of the recently discovered serious arrhythmic disorders.  
Features compatible with LQTS may have been reported in 1856 when Meissner described a 
young deaf girl who died suddenly after being scolded at school and whose two brothers had 
died during intense fright and rage (Meissner 1856). In 1957, when registering the ECG had 
been made possible, a long QT-interval and arrhythmia were linked to the syndrome of 
congenital deafness and sudden death (Jervell et al 1957). Jervell correctly identified the 
syndrome now bearing his name as a recessive disorder. In the original report, four deaf 
children with two unaffected siblings were the offspring of two nonconsanguinous parents. 
Later, in the mid-1960s, another related arrhythmic syndrome without congenital deafness, 
subsequently known as Romano-Ward syndrome was described (Romano 1963,Ward 1964). 
The theory at that time maintained that the underlying defect in LQTS was a dysequilibrium of 
the sympathetic and parasympathetic nervous systems in regulation of cardiac function (Moss 
1971).
Much later, it was suspected that under the diagnosis of LQTS (i.e. Romano-Ward syndrome) 
there existed several phenotypically different forms of the same disease. In 1991 Keating 
confirmed that LQTS had a genetic basis. Finally, in the mid-1990s, it was discovered that 
LQTS is what is now called a channelopathy. 
When this thesis was being planned in 1998, it was known that mutations in four genes 
encoding cardiac ion channel proteins cause the long QT syndrome: the first was KCNQ1, then 
called KvLQT1, the second KCNH2, then called HERG after human ether-à-go-go related 
channel, the third SCN5A and the fourth KCNE1, then called MinK or minimal potassium 
channel. The corresponding disease subtypes were called LQT1-3 and LQT5, respectively. The 
KCNQ1 and HERG genes code for potassium channel ?-subunits and the SCN5A gene for a 
sodium channel, while the KCNE1 gene codes for a potassium channel ?-subunit (Curran et al 
1995, Wang et al 1995, Barhanin et al 1996, Splawski et al 1997). It was also suspected that 
other subtypes were yet to be found. Little was known about the modulation of these currents 
or why symptoms tended to occur in response to different triggers in LQTS subtypes. By the 
year 1998, no polymorphisms of these channels influencing phenotypic characteristics had 
been reported.
Subsequently, mutations underlying LQTS were reported in the ankyrin gene encoding for a 
scaffolding protein (LQT4), the potassium channel ?-subunit genes KCNE2 (LQT6), and in the 
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potassium channel KCNJ2 (LQT7) (Abbott et al 1999, Tristani-Firouzi et al 2002, Mohler et al 
2003). Until May 2006, over 300 different mutations and over 30 single nucleotide 
polymorphisms have been found in the LQTS-genes (Aydin et al 2005, Roberts et al 2006).  
2.2 Clinical features of LQTS 
2.2.1 Prevalence and inheritance 
Jervell-Lange Nielsen syndrome. Jervell-Lange Nielsen is an autosomal recessive disorder 
implying that two defective alleles are needed for the individual to be affected. Homozygous 
mutations in the KCNQ1 gene as well as compound heterozygous mutations in the KCNE1 and 
KCNQ1 gene cause this rare disease, which accounts for less than 10% of total cases of LQTS 
(Neyroud et al 1997, Splawski et al 1997, Splawski et al 1997, Tyson et al 1997). It has been 
estimated that 2 to 3 per thousand congenitally deaf individuals are affected by this syndrome 
(Fraser et al 1964, Schwartz 1975, Roden et al 2000).  
Romano-Ward syndrome. The Romano-Ward syndrome is inherited in an autosomally 
dominant fashion. This means that if one parent is a carrier of an LQTS mutation, half of the 
offspring will be affected. The present study focuses on the Romano-Ward syndrome, now 
further classified into at least seven subtypes (LQT1-LQT7). A prevalence of one in five 
thousand has been suggested in Finland (Piippo et al 2000) and one in ten thousand elsewhere 
(Vincent et al 1998). It has been suggested that patients presenting with arrhythmia, 50% die 
within 10 years if left untreated (Marian et al 2004). 
2.2.2 Clinical characteristics of LQTS 
Triggering factors. In previous studies, LQT1 has been associated with symptoms occurring 
during exercise and occasionally during emotion (Garson et al 1993, Ali et al 2000, Schwartz 
et al 2001, Choi et al 2004). An arrhythmia-trigger relatively specific for LQT1 is swimming 
(Ackerman et al 1999, Choi et al 2004). 
In LQT1 patients, up to 62% of symptoms occurred during exercise and only 3% during rest or 
sleep. Arrhythmias in LQT1 appear to require a high heart rate and activation of the 
sympathetic nervous system, conditions shown in a cellular models to favor induction of 
torsade des pointes as a result of reentry (Shimizu et al 1998). In addition, it seems that 
adrenergic tone is often longstanding before arrhythmia occurs in LQT1, in contrast to LQT2 
in which short surges of adrenergic tone can cause arrhythmia (Lu et al 2001). 
Correspondingly, epinephrine infusion has been noted to lengthen repolarization as defined by 
the QT-interval in LQT1 but not LQT2 (Ackerman et al 2002, Shimizu et al 2003). According 
to a recent study in LQT1 patients, location of the mutation does not influence clinical 
presentation, ECG parameters or cardiac events (Zareba et al 2003). However, view on this are 
differing, as Shimizu and colleagues have suggested that transmembrane mutations in LQT1 
are more malignant then C-terminal ones, while Moss and Shimizu found that mutations in the 
pore region confer more arrhythmic risk (Moss et al 2002, Shimizu 2004). Gender has a 
clearcut influence on the manifestations of LQTS. Female LQTS patients have longer QT-
intervals and are more likely to experience arrhytmic episodes (Drici et al 1998, Priori et al 
2003). It has been shown that LQT1 males are likely to experience symptoms at an early age, 
whereas in LQT1 and LQT2 females experienced more cardiac events during adulthood 
(Zareba et al 2003).
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LQT2 patients, on the other hand, tend to develop arrhythmia during emotional stimulation or 
acute arousal from rest at rest or during sleep, especially when awakened suddenly (Wilde et al 
1999, Schwartz et al 2001, Priori 2003). Less than a third of cardiac events were exercise-
related in LQT2 patients (Schwartz et al 2001). Particularly symptoms upon waking up to an 
auditory stimulus such as an alarm clock are frequent in LQT2 patients when compared to 
LQT1 patients (Moss et al 1999). This has been suggested to be a useful method for 
differentiation of LQT1 and LQT2 as only 2% of LQT1 but up to 26% of LQT2 patients had 
auditory stimuli-related symptoms (Wilde et al 1999).  
Heart rate. Another factor possibly predicting symptomaticity in LQTS patients carrying a 
South African founder mutation seems to be resting heart rate. Carriers of a KCNQ1 mutation 
A341V were more likely to be symptomatic if they had higher resting heart rates as a marker of 
increased basal sympathetic nervous system tone (Brink et al 2005).  
Resting QT-interval. On the ECG, the QT-interval is approximately the same as the duration of 
repolarization which is the time interval from the depolarization of the ventricles to the end of 
the action potential (Franz et al 1987, Suracwicz et al 1987). It has been shown that the QT-
interval corresponds to the monophasic action potential registered from the myocardium (Franz 
et al 1987). Due to its proximity to the interventricular septum and therefore the ensuing high 
amplitude of the T-wave, the QT-interval from lead V2 or V3 is considered best for 
determining QT-interval in both healthy and non-healthy individuals (Cowan et al 1988).
Traditionally, the QT-interval adjusted according to the Bazett square root formula [QT/(RR in 
seconds)1/2] (Bazett 1920) has been used in the diagnosis of LQTS with a “cut-off” value of 
440 or 450 ms. Other formulas have also been used, for example the Fridericia cubic root 
formula [QT/(RR in seconds)1/3] (Fridericia 1920), the linear regression formula as used in the 
Framingham study (QT+0.154x[1-RR in seconds]) (Sagie et al 1992), and the Hodges formula 
(QT + 105 (1/RR − 1).
However, in a large multicenter study, different formulae were used for the measurement of the 
QT-interval (Bazett, Fridericia, Framingham and Hodges) (Luo et al 2004). Surprisingly, if the 
upper normal limits of the QTc were determined by excluding the longest 2%, the upper limits 
of these formulas would be Bazett 483 ms, Fridericia 460 ms, Framingham 457 ms and Hodges 
457 ms. If a cut-off of 420 or 440 ms would be used, this would mean that 30% of normal 
ECGs would be classified as abnormal (Luo et al 2004). This is why the QTc-interval does not 
reliably differentiate between patients and controls reliably (Moss et al 2005) except in LQT3 
(Brouwer et al 2003).
It has  been shown that up to 40% of LQT1 and LQT2 patients and up to 10% of LQT3 
patients have normal QT-intervals (Schwartz et al 1980, Vincent et al 1992, Piippo et al 2000, 
Priori et al 2003, Zareba et al 2003, Napolitano et al 2006). Of the QT-interval correction 
formulas mentioned above, the Bazett method performs poorest at all heart rates except at 
resting conditions and the Fridericia method performs poorly at high heart rates (Franz et al 
1987, Karjalainen et al 1994). The linear regression method has been considered to perform 
best at all heart rates but is not widely used (Karjalainen et al 1994). However, none of these 
QT-interval adjustment formulas produces a linear relationship between QT-interval and heart 
rate at all heart rates meaning that adjusted QT-intervals at different heart rates cannot be 
compared (Davey et al 1999).  
In LQTS patients, the longer the QTc-interval is, the more likely the patient is symptomatic or 
at risk of symptoms (Priori et al 2003). This observation is not limited to LQTS patients, as in a 
population of adults aged over 55 years, those with a prolonged QTc were more likely to die a 
sudden cardiac death (Straus et al 2006). 
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T-wave morphology. Roughly, the myocardium is composed of three layers, the endocardium 
on the inside, the layer of M-cells in the mid-myocardium and the epicardium on the outside. 
In the healthy heart, the inner layer of the heart repolarizes before the outer layer. Opposing 
voltage gradients between the epicardium and the M region as well as the endocardium and the 
M region contribute prominently to the inscription of the T-wave under normal conditions and 
to the widened or bifurcated T-wave and long QT-interval during acquired LQTS and in 
congenital LQTS patients (Yan et al 1998). In LQTS, different ratios in the current density of 
INa, IKr and IKs in different parts of the myocardium contribute to longer and shorter action 
potentials with epicardial cells having shorter action potentials and endocardial and especially 
M-cells having progressively longer action potentials (Yan et al 1998, Viswanathan et al 1999). 
These voltage gradients between different regions of the myocardium cause chaotic electrical 
activity by way of membrane potential differences between different parts of the myocardial 
wall. In resting ECGs, notched T-waves at different heart rates have also been shown to be a 
relatively specific marker of LQT2 (Malfatto et al 1994, Dausse et al 1996, Zhang et al 2000, 
Lupoglazoff et al 2001). LQT1 patients have broader, longer T-waves and LQT3 patients a T-
wave with an unusually late onset and large amplitude. However, the value of the T-wave in 
determining genotype is limited because intra- and interindividual variation in T-wave shape is 
significant (Figure 1)(Moss et al 2002).
Torsade des pointes. As its French name implies, the typical LQTS-associated ventricular 
tachycardia is characterized by “twisting of the points” along the isoelectric axis (Dessertenne 
et al 1966). However, a polymorphic ventricular tachycardia indistinguishable from torsade des 
pointes can occur as a result of hypokalemia, hypomagnesemia, hypocalcemia, severe 
bradycardia, ischemic heart disease, right ventricular cardiomyopathy and dilated 
cardiomyopathy (Gowda et al 2004). Torsade des pointes is important to identify, as its 
treatment is different from other ventricular tachycardias (Tzivoni et al 1988, Monraba et al 
1999).
Why torsade des pointes persists in the myocardium is not completely clear. It is a re-entry 
tachycardia that probably persists due to transmural dispersion and disproportionate action 
potential prolongation (Belardinelli et al 2003). Fortunately, in most cases it self-terminates 
before ventricular fibrillation and death.
In LQTS, early afterdepolarizations (EADs) are the trigger for torsade des pointes (Viskin et al 
2000). It has been held that EADs arise in either the Purkinje cells near the endocardium (El-
Sherif et al 1990), or, alternatively, in the M-cells where the action potential is excessively 
prolonged (Antzelevitch et al 1994, Antzelevitch et al 1999). The question is, how is it that the 
local EADs lead to ventricular tachycardia of the Torsade des pointes type in LQTS-patients. 
According to a recent study, arrhythmia is triggered as a result of EADs and the breakthrough 
spot from where the arrhythmia propagates to the ventricle is in the region where the 
repolarization gradients are most intense (i.e. where regions near to one another were in 
different stages of repolarization) (Liu et al 2005).  
Review of the Literature 
14
Figure 1. ECGs during rest and exercise in two LQT1 patients and one LQT2 and LQT3 
patient.
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2.2.3 Non-invasive electrophysiology 
Exercise tests. The heart rate response of the QT-interval during and after exercise has been 
looked into in several studies. In most studies, the QT-interval in LQTS has shortened 
inadequately or even lengthened (Shimizu et al 1991). The relationship of QT to heart rate in 
each subject was examined by plotting QT duration against heart rate (ms/min−1) and 
calculating the slopes by least squares linear regression analysis in each individual to determine 
QT/HR slopes by Swan et al (Swan et al 1999). QT-interval shortening in LQT1 and controls is 
similar, but QT-interval shortens more in relation to heart rate in LQT2 (Swan et al 1999), 
which is in accordance with the fact that stimulation of the sympathetic nervous, namely, ?1-
adrenergic stimulation system increases the slow component and decreases the rapid 
component of the delayed rectifier potassium current (IKs and IKr, respectively) (Thomas et al 
2004, Iost et al 2005).  However, the QT/HR slopes in individual patients overlapped widely. 
During recovery it was noted that LQT1 and LQT2 patients had steeper QT/HR slopes than 
controls. According to recent data, the best separation between patients and controls may be 
obtained by measuring QTc at 3 minutes into the recovery period (Dillenburg et al 2001).
Another variable, Tpe (duration from the peak to the end of the T-wave) has been noted to 
increase during exercise in LQT1 patients but not in LQT2 patients, which may partially 
account for the finding that fatal cardiac events in LQT1 are more often associated with 
exercise (Takenaka et al 2003). In a very different approach, LQT1 and LQT2 patients as well 
as LQTS patients of an unknown genotype exercised on a bicycle ergometer for 1 minute 
against a fixed 200 W workload. This test distinguished latent LQTS patients, or those with a 
normal QTc but with a proven disease-causing mutation or LQTS phenotype from controls. 
LQTS patients had marked QTc prolongation during the exercise protocol (Walker et al 2005). 
In another study, non-genotyped LQTS-patients could not be distinguished from controls when 
QT/RR slopes and T-wave complexity was analyzed during sudden intense exercise (Chauhan 
et al 2004).
The exercise test moderately improves the sensitivity and specificity of other tests for clinical 
diagnosis of LQTS. However, as with resting ECGs, significant overlap exists during exercise 
ECGs at a given heart rate between controls and LQTS (Swan et al 1999) and therefore the 
exercise test is not very efficient in diagnosis of LQTS but can strengthen the suspicion of 
LQTS until a molecular genetic diagnosis can be made. 
Holter recordings. Because of the limitations of the resting ECG in differentiating LQT1 from 
LQT2, Holter recordings have been used experimentally for this purpose, as more T- and U-
waves, also called T1- and T2-waves (Viitasalo et al 2006), can be simultaneously analyzed 
from a Holter recording than a normal ECG (Eggeling et al 1992, Merri et al 1992). It has been 
noted that at slow heart rates, the QT-intervals in LQT2 and LQT3 are longer than in LQT1. 
During exercise, LQT1 patients have the longest QT-intervals (Nemec et al 2004). QT 
duration, QT-interval rate dependence and the interval between the Q-wave and the apex of the 
T-wave subtracted from the interval between the Q-wave and the end of the T-wave (QTend-
QTapex) as a marker of temporal dispersion of repolarization have also been used to 
differentiate LQT1 and LQT2 (Viitasalo et al 2002, Viitasalo et al 2002). According to these 
studies, LQT2 patients had greater transmural dispersion of repolarization than LQT1 patients 
indicating that the duration of the action potential of myocardial cells in different layers of the 
myocardium differ more than in controls. However, this variable was not related to 
symptomaticity. Furthermore, the ratio of early T-wave peak amplitudes in 24-hour ECGs 
seems to offer a noninvasive albeit difficult to obtain marker for differentiation of symptomatic 
and asymptomatic LQTS patients from each other. The maximal amplitude ratios between 
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early and late T-wave peaks were higher in symptomatic LQT1 and LQT2 patients (Viitasalo et 
al 2006).
Endocardial monophasic action potential recording. Despite being a common cause of sudden 
death, the genesis of ventricular tachycardia and ventricular fibrillation remains poorly 
understood (Weiss et al 2000). Theoretical and cell model studies have been used to investigate 
how arrhythmias arise in the myocardium. However, due to the exact nature of different 
currents in the human myocardium being unknown, these models cannot be completely 
realistic. Secondly, models are usually two-dimensional, whereas the human heart is a complex 
three-dimensional structure.  
In intact guinea pig hearts and healthy humans it has been shown that action potential duration 
at progressively longer cycle lengths is related to the extrastimulus cycle length exhibiting a 
biphasic electrical restitution curve (Watanabe et al 1995, Zeng et al 1995). The time interval 
from the last of a train of regularly introduce pacing stimuli to the extrastimulus is called the 
coupling interval. The shortening of action potential duration, as coupling interval shortens, 
and its respective lengthening as coupling interval lengthens, is called action potential 
restitution. The standard restitution curve is generated by applying a single pulse (S2) at 
various coupling intervals following a train of steady-state pulses (S1). The shortest possible 
coupling interval that conducts 1:1 is the refractory period of the heart and under ideal 
conditions, this is usually the shortest S1-S2 interval used. The activation of IK, composed of 
IKr and IKs plays a major part in determining action potential length. Increased action potential 
duration restitution contributes to recovery of excitability and creates conditions favoring 
reentry and arrhythmia (Hondeghem 2001). Earlier, several factors have been implicated in 
restitution: K+ accumulation, K+ current activation, Na+  window current activation and Ca2+
current activation. Blocking 50% of IK in a Luo-Rudy 1 cell model was more effective than 
50% block of INa or ICa in steepening the restitution slope over a wide range of diastolic 
intervals theoretically leading to arrhythmia (Weiss et al 1999). If the slope of the restitution is 
larger than one, rapid pacing induces alternans and fibrillation in isolated ventricles due to 
chaotic electrical activity as reported by Franz (Franz 1987). In another report after steady-state 
pacing of more than 100 beats, even very short diastolic intervals did not incur significant 
action potential duration alternans (Banville et al 2004).  Alternans is seen as T-wave alternans 
on the ECG, which is a well-established predecessor of ventricular arrhythmias (Nearing et al 
1991).
Interventional studies. Epinephrine-induced QT-interval prolongation has been proposed to be 
pathognomonic for LQT1 (Noda et al 2002, Shimizu et al 2003). In particular, low-dose 
epinephrine infusion distinguishes LQT1 patients from LQT2 patients and controls (Ackerman 
et al 2002). In LQT1 patients, this prolongation appears to persist during continued epinephrine 
infusion, but in LQT2 patients it is transient, disappearing even though epinephrine infusion 
continues. A similar observation was made by Kaufman et al. (Kaufman  et al 2005) and it has 
been suggested that an epinephrine infusion of 50 ng/kg/min could be used as a clinical test for 
predicting the presence of LQT1 mutations (Perry et al 2002). These events may be due to the 
gradual increase of IKs and the decrease of IKr as adrenergic stimulation continues.  
In another study in a group of “latent” LQTS patients, with ≤ 2 points as determined by the 
Schwartz criteria (Schwartz et al 1993) (Table 2), it was noted that epinephrine bolus followed 
by epinephrine infusion was effective in diagnosing latent LQTS syndrome. In this study 
QTend, QTpeak, QTend-peak absolute values as well as QTend and QTpeak adjusted to the Bazett’s 
formula were increased in LQT1 patients with a ”latent” phenotype to the same extent as in 
those with manifest LQTS (Shimizu et al 2003).  
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For more than ten years it has been known that early afterdepolarizations contribute to 
arrhythmia (Shimizu et al 1991, Pelleg et al 1995). Isoproterenol has been found to induce 
early afterdepolarizations in non-genotyped LQTS-patients while beta-blockers were found 
suppress them (Shimizu et al 1997, Shimizu et al 2000). In genotyped patients, epinephrine 
increases QT-dispersion, suggesting that ?-adrenergic stimulation causes arrhythmia by 
contributing to inhomogeneity of action potential duration across the myocardium (Sun et al 
1998). Under normal conditions, repolarization of the ventricle takes place as follows: first the 
epicardium, then the endocardium and finally the M-region. Non-homogeneity in this sequence 
gives rise to transmural dispersion of repolarization, which is modest and nonarrhythmic in 
healthy individuals, but potentially arrhythmogenic in LQTS patients (Antzelevitch et al 1998).  
Figure 2. Early afterdepolarizations. Arising from a low membrane potential, an 
afterdepolarization occurs before full repolarization of the cells initially depolarized in the 
main potential.  
2.2.4 Clinical diagnostics 
Diagnostic criteria. The first diagnostic criteria for the diagnosis of LQTS were proposed in 
1985 (Schwartz et al 1985) (Table 1). However, since healthy individuals can have lengthened 
QT-intervals and LQTS patients can have normal QT-intervals, as evidenced by linkage 
studies, a new set of criteria was developed in 1994 (Schwartz et al 1993) (Table 2). Using 
these diagnostic criteria, a definite LQTS diagnosis is defined by an LQTS score of ?4.
Table 1. Schwartz criteria 1985.  
MAJOR CRITERIA MINOR CRITERIA 
Prolonged QT over 440 ms Congenital deafness 
Stress-induced syncope Episodes of T-wave alternans 
Family memebers with LQTS Low heart rate 
 Abnormal ventricular repolarization 
Diagnosis of LQTS can be made in the presence of 2 major or 1 major and 2 minor criteria.   
–80 mV
0 mV
+30 mV
Early
Late
Na+ entry
Na+, Ca2+ entry
K+ exit
After-
depolarization
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Table 2. Schwartz criteria 1993. A total of ?4 points indicates a definite diagnosis of LQTS. 
ECG* Points 
  A. QTc-interval †  
     ? 480 ms 3 
     460-470 ms 2 
     ? 450 ms in males 1 
  B. Torsade des pointes‡ 2 
  C. T-wave alternans 1 
  D. Notched T-wave in three leads 1 
  E. Low heart rate for age 0.5 
Clinical history  
  A. Syncope‡  
      With stress 2 
      Without stress 1 
  B. Congenital deafness 0.5 
Family history (either A or B)  
  A. Family members with definite LQTS 1 
  B. Unexplained sudden cardiac death below age   
      30 among immediate family members 
0.5 
*In the absence of QT interval prolonging drugs or conditions. 
†QTc as determined by the Bazett formula 
‡Mutually exclusive 
§Below second percentile for age 
2.2.5 Treatment and prophylaxis of arrhythmia in LQTS 
Treatment of torsade des pointes. Treatment of torsade des pointes must be initiated as soon as 
it is noted. Most often torsade des pointes is self-limiting, but if untreated, it may degenerate 
into ventricular fibrillation and eventually death. The relatively safe first-line therapy for 
torsade des pointes is magnesium sulphate as a bolus of 2 g intravenously which can be 
repeated up to a dose of 6 g. Magnesium acts by decreasing the movement of calcium ions into 
the cell (Viskin et al 1999). The causes of torsade des pointes such as QT-prolonging 
medications and electrolyte abnormalities, most often hypokalemia, must also be eliminated. 
Other treatment options are percutaneous or transvenous overdrive pacing to increase the heart 
rate to 100-150 (Monraba et al 1999, Viskin et al 1999) and ß-blockers which have been 
proven to prevent the induction of torsade des pointes in an LQT1 model (Shimizu 1998). It 
has been postulated that ß-blockers act by decreasing ICaL (Shimizu 1998). In case torsade des 
pointes degenerates into ventricular tachycardia, first-line therapy is defibrillation.
Treatment of LQTS. A reliable diagnosis of LQT1 or LQT2 (or LQT3) should be reached of 
excluded as soon as syncope and a lengthened QT-interval are diagnosed. In a population of 
symptomatic LQT patients lifetime lethal events are more frequent in LQT1 than LQT2 
(lifetime LQTS related death rates of 40 and 28%, respectively) and even more frequent in 
LQT3 (a death rate of 49%) (Schwartz et al 2001). This is a reason why ?-blocker therapy 
should be initiated early in patients with an LQT1 genotype because LQT1 patients respond 
clearly better to high-dose ?-blocker therapy than LQT2 patients (Priori et al 2004, Wedekind 
et al 2004).
Both LQT1 and LQT2 patients tolerate ?-blocker therapy well, but in LQT3 patients these 
drugs might be detrimental due to the heart rate slowing elicited by these drugs (Shimizu et al 
2000). Overall, ?- blockers are most effective in LQT1 (only 10% remain symptomatic), and 
less effective in LQT2 and LQT3 (24% and 32% remain symptomatic, respectively) (Priori et 
al 2004). In another study  as many as 25% of genotyped LQTS (LQT1, LQT2, LQT3) 
pediatric probands experienced “breakthrough” symptoms (syncope, aborted cardiac arrest, 
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apprioriate implantable cardioverter-defibrillator shocks, sudden cardiac death) during a 
follow-up of 46 months; risk factors for symptoms were treatment with atenolol, young age at 
diagnosis, initial presentation with aborted cardiac arrest, LQT1 and noncompliance (Chatrath 
et al 2004). Other treatment options aside from β-blockers in LQTS are permanent pacing 
(Moss et al 1991), left cardiac sympathetic denervation (Moss et al 1971, Nalbantgil et al 1972, 
Schwartz et al 2004), and defibrillator implantation (Gronefeld et al 1996, Zareba et al 2003, 
Goel et al 2004). It has recently been postulated, that in LQT2, long-term potassium therapy 
could be used to correct repolarization abnormalities (Etheridge et al 2003). Further studies are 
needed, however, to determine whether long-term potassium therapy also prevents life-
threatening arrhythmias. 
The importance of behavioral counselling of LQTS patients  should not be underestimated 
(Maron et al 2004). Long QT patients are recommended to avoid physical activities involving 
rapid acceleration or deceleration such as basketball, ice hockey, soccer and tennis as well as 
sports involving swimming, such as lap swimming, scuba diving and windsurfing. It is also 
recommended that whatever the sport, LQT1 patients should refrain from competitive sports 
and when swimming, have someone accompany them. LQT2 patients should remove alarm 
clocks and telephones as well as other potential sources of startling auditory stimuli from their 
bedrooms (Schwartz et al 2001). With LQT3 it is not so simple, as mutation carriers can have 
symptoms during exercise, as a response to an external stimulus, during physical inactivity 
awake or during sleep. 
It has been recommended that prophylactic treatment be commenced in carriers of a KCNQ1
mutation who have a QT-interval of 500 ms or more, male carriers of a KCNH2 mutation with 
a QT-interval of 500 ms or more and all female carriers of a KCNH2 mutation. No randomized 
trials exist as the sodium channel blocker mexiletine improves survival in LQT3. Also, it is not 
clear, whether all LQT3 mutation carriers should have implantable cardiac defibrillators 
(Splawski et al 2000, Priori et al 2003).
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2.3. Molecular genetics of LQTS 
2.3.1 Cardiac ion channels and their role in the cardiac depolarizatio-
repolarization cycle 
The functioning myocardium is a fine-tuned organ that ideally functions satisfactorily for the 
many decades of an individual’s life, beating up to 90,000 times a day and up to 3 billion times 
in 80 years. Like the brain and skeletal muscle as well as most of the other tissues in the human 
body, it depends on ion channels in order to function.
Ion channels are proteins spanning the lipid bilayer of the cell membrane. In the human 
myocardium, a large amount of energy is required to maintain the gradient of sodium and 
potassium ions across the cell membrane. This energy is unleashed by small conformational 
changes in ion channels, which allow millions of ions to flow in or out of the cell during the 
action potential. These channels are classified according to the ion they mainly conduct; 
sodium, potassium, chloride or calcium ions.  
Figure 3. Cardiac ion channels and their respective currents during the cardiac action potential. 
Currents are depicted as a function of time. Amplitudes in figure do not correlate to amount of 
current during the action potential. INa cardiac sodium current, ICa-L cardiac L-type calcium 
current, ICa-T cardiac T-type calcium channel, INa/Ca cardiac sodium/calcium exchanger, ITo1 and 
ITo2 transient outward currents, IKs slow component of the delayed rectifier potassium current, 
IKr rapid component of the delayed rectifier potassium current, IKur cardiac voltage-gated 
potassium channel, IKp time-independent background current, IK1 pacemaker current.  
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Ligand-gated ion channels are gated by intra- or extracellular ligands, while voltage-gated 
channels are gated by transmembrane voltage (Ackerman et al 1997, Marban et al 2002, Roden 
et al 2002). In voltage-gated channels a change in transmembrane voltage switches on the 
channel and increases its conductance many thousandfold. These channels are influenced by 
many other factors beside transmembrane voltage, including channel phosphorylation, changes 
in channel oxidation-reduction, changes in channel cytoskeleton, cellular calcium or cellular 
adenosine triphosphate concentrations. LQTS is caused by flaws in voltage-gated potassium 
channels or their subunits or sodium channels.  
IK was first characterized in rabbit cardiac myocytes (Shibasaki et al 1987) even before the 
separate components of IK, IKr and IKs were discovered (Sanguinetti et al 1990). KCNH2 is a 
tetrameric protein composed of four identical subunits containing six transmembrane spanning 
domains (S1-S6) and a pore-forming region (P-region extending from S5 to S6). KCNH2 is 
thought to represent the α-subunit and KCNE2 the β-subunit of a channel that has the 
biophysical properties of the rapid component of IK, also known as the inward rectifier 
potassium current (IKr). Inward rectification is a property that limits outward current through 
the channels at positive voltages, namely the plateau phase of the cardiac action potential. 
Whether KCNH2 and KCNE2 fully account for IKr, however, is still an open question, as closer 
inspection of the current produced when these two channel subunits are coexpressed revealed 
that the role of KCNE2 is not that of a necessary constituent of the KCNH2 complex 
(Weerapura et al 2002).  
KCNQ1 and KCNE1 make up the slow component of IK, (IKs) which exhibits a more linear 
current-voltage relationship. KCNQ1, like KCNH2, is a typical K+-channel ?-subunit
containing 676 amino acids with a structure similar to KCNH2 (Tseng et al 2001). KCNE1 is a 
smaller regulatory ?-subunit.
Figure 4. KCNQ1 + KCNE1 and KCNH2 (+KCNQ2). A schematic picture of the predicted 
transmembrane topology of the ?- and ?-subunits making up the IKs, and IKr channels, 
respectively. The potassium channels are formed by six transmembrane domains, an 
intracellular C-terminus, and an extracellular N-terminus.  
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The duration of the cardiac action potential is determined by a balance of inward and outward 
ion channel function. Therefore, an increase in inward current or a decrease in outward current 
prolongs the repolarization of the cardiomyocyte (Luo et al 1991, Luo et al 1994). At the 
resting membrane potential the cardiomyocyte is highly permeable to K+ ions as the cell 
membrane potential is close to the Nernst potential of potassium which is -98 mV (Ackerman 
et al 1997). The Nernst potential is the potential at which an equilibrium exists between ionic 
concentrations intra- and extracellularly. KCNQ1 and KCNH2 channels exist  in one of three 
forms: closed, open and inactive. The change from closed to open is called activation, while the 
change from open back to closed is called deactivation. An inactivated state of the channel 
implies that it is open but unable to conduct potassium ions.  
                                           ACTIVATION     INACTIVATION 
? ?
                               CLOSED                     OPEN                  INACTIVATED 
? ?
                                         DEACTIVATION    RECOVERY FROM
                                                                             INACTIVATION 
During depolarization, membrane voltage quickly rises above 0 mV as a result Na+ and L-type 
Ca2+ channels. However, IKr conducts very little current at this stage. This is because KCNH2 
channels pass from an open to an inactivated state as membrane voltage rises with most of IKr
being inactive at higher voltages. During the plateau or phase 2 of the action potential, a 
balance of inward L-type Ca2+ and outward delayed rectifier potassium channels create an 
equilibrium lasting a few hundred milliseconds (Figure 3). Then, as a result of a gradual 
increase in IKs and IKr and with inactivation of Ca2+ channels, phase 3 brings the heart back 
toward the resting potential again (Lindemann et al 1990, Rosen et al 1992). This massive 
outflow of potassium from the cell is due to the rapid recovery from inactivation which is 
characteristic of the IKr current. IKs is more active during the end of phase II or plateau phase of 
the action potential while IKr predominates during the phase III return to resting membrane 
potential (Viswanathan et al 1999). As a result, the cardiac action potential is terminated to be 
held for the duration of phase 4 at -98 mV and to be activated again by the aforementioned 
Na2+ and L-type Ca2+ channels.
2.3.2 In vitro electrophysiology 
The technique of patch clamp recording was invented by Bert Sakmann and Erwin Neher in 
1981 for which they received the Nobel prize. The term patch-clamp refers to the ”clamping” 
of the membrane potential in order to study voltage-gated channels. The principle of patch 
clamping is to isolate a patch of membrane electrically from the external solution and to record 
current flowing into the patch. 
This techniques allows the examination of characteristics of ion channels using either the 
single-channel or whole cell approach (Ogden and Stanfield 1994). In the single channel 
approach, only one or usually a handful of channels on the cell membrane are studied. In the 
whole cell approach, the entire channel population on the cell membrane is examined and the 
currents in whole cell measurements are the sum of thousands of channels opening, 
inactivating and deactivating. In our studies we used the whole-cell method.  
In investigating the physiology and pathophysiology of ion channels, various cells have been 
used including mammalian cells (most often guinea pig or canine cardiomyocytes), human 
cardiomyocytes, undifferentiated mammalian cells and Xenopus oocytes. Relatively 
undifferentiated mammalian cells such as COS-7 (immortalized African green monkey 
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kidney), HEK-293 (immortalized human embryonic kidney) and CHO (immortalized Chinese 
hamster ovary) cells, are easiest to use due to their lack of native currents and ease of 
cultivation (Seebohm et al 2001). 
In a typical experiment, a polished glass pipette with a diameter of 10-25 ?m, filled with 
intracellular solution, is applied against the surface of a cell. As the pipette is lowered to the 
cell membrane, slight positive pressure is maintained to keep the pipette clean. As the cell 
pipette approaches the cell, light suction is applied to seal the tip of the pipette onto the cell to 
form a “gigaseal” followed by a stronger suction to rupture the cell membrane and to attain 
whole-cell mode is attained. After establishing the seal, the fast capacity transients associated 
with pipette capacitance to the bath are compensated. The potential of the pipette interior is 
adjusted/compensated to a level similar to the anticipated membrane potential of the cell. If the 
pipette and cell surface are clean, a seal whose electrical resistance is more than 10 (preferably 
close to 100 G?) is formed. A high seal resistance is needed for more complete electrical 
isolation of the patch and to keep the noise level as low as possible. After these adjustments, 
cell voltage is altered and corresponding ion currents are monitored. 
2.3.3 Molecular pathology of LQTS 
When IKr and IKs do not function properly, the repolarization of the heart is abnormal, and, in 
fact, LQTS is in essence a disease of cardiac repolarization which is seen as a prolongation of 
action potential duration. Defective potassium channel activation, deactivation, inactivation or 
any combination of these can be responsible (Tseng et al 2001). Errors in these processes are 
made more significant by the fact that the IKr current is the target of a group of widely used, 
potent and specific class III antiarrhythmic drugs, the methanesulfonanilides (Sanguinetti et al 
1990,Spector et al 1996). Figure 5 is an illustration of a monophasic action potential tracing, 
the IKr current tracing and an ECG tracing in LQTS.  
Figure 5. The action potential and the IKr current. During the downsloping phase 3 of the action 
potential there is a gradual increase in IKr current as channels open to deactivate as membrane 
potential nears the resting state. If this increase is lacking, the QT-interval is prolonged (lower 
part of figure).
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Channel kinetics of IKr. Potassium channel deactivation is a major determinant of action 
potential duration (Zhou et al 1998). Deactivation kinetics of the KCNH2 channel are slow at 
all voltages, especially the voltages relevant to the end of the human cardiac action potential 
when current density of the KCNH2 channel is greatest. If channel deactivation is enhanced, 
repolarization of the cardiomyocyte would take place with slower speed, with prolongation of 
action potential duration and the QT-interval. Deactivation is mainly determined by the N-
terminus of the KCNH2 channel. Thus, deletion of the first 354 to 370 amino acids of the 
KCNH2 protein results in a channel with very rapid deactivation and slow inactivation 
(Schonherr et al 1996). LQT2 mutations exhibiting altered deactivation, for example the 
KCNH2-Fin (L552S), have been shown to cause LQTS (Piippo et al 2000).
The rapid inactivation and recovery from inactivation is an essential feature of the KCNH2 
channel which allows the channels that are open and inactivated to open as membrane voltage 
drops (Rasmusson et al 1998, Kiehn et al 1999, Tseng et al 2001). The inactivation kinetics of 
KCNH2 are much more rapid than that of other voltage-gated K+ channels. Inactivation can be 
altered by LQTS mutations. These mutations reside mainly in the S5-P(ore) loop of the 
KCNH2 protein and influence C-type inactivation (Tseng et al 2001). C-type inactivation is the 
type of inactivation insensitive to deletion of the N-terminus and has sometimes been referred 
to as ”slow inactivation”, occurring over a period of several hundred milliseconds (Aydar et al 
2001). It involves closure of the extracellular mouth of the pore that occludes the flow of 
potassium ions. The other inactivation type is the ”ball and chain” mechanism. A small group 
of residues in the N-terminus bind to the activated channel and occlude the intracellular mouth 
of the channel. This N-type inactivation is very quick, occurring in milliseconds to tens of 
milliseconds, was formerly referred to as fast inactivation.  
Altered rates of inactivation and recovery from inactivation have been observed in KCNH2 
channels affected by mutations located in the S4 region and the outer mouth of the pore region 
as well as the C-terminus (Berthet et al 1999, Aydar et al 2001, Sasano et al 2004, Teng et al 
2004). The K897T polymorphism first reported by Laitinen et al and studied in the present 
study is situated in the C-terminus (Laitinen et al 2000). These data indicate the complex nature 
of the inactivation process. Therefore, the single rate constants (?
-on, steady state inactivation 
and ?
-off) used in studies describing the inactivation kinetics of the KCNH2 channel may not 
fully describe the inactivation process.  
Locally acting mediators may also modify IKr. Local potassium concentration is an important 
determinant of IKr current amplitude and deactivation kinetics (Scamps et al 1989, Sanguinetti 
et al 1992, Yang et al 1997). Paradoxically, the higher the potassium concentration is, the 
larger IKr current amplitude is. 
Channel kinetics of IKs. KCNQ1 ?- and KCNE1 ?-subunits are responsible for IKs, the large, 
slowly activating (“delayed”) outward rectifying potassium current. The deactivation kinetics 
of IKs are more rapid than those of IKr. In spite of the rapid deactivation kinetics, it seems that 
as heart rate increases and RR-interval shortens, KCNQ1 + KCNE1 channels fail to deactivate 
completely, resulting in an additive effect on the number of open and conducting channels 
(Terrenoire et al 2005). Very little data exists on IKs in human cardiomyocytes (Virag et al 
2001).
IKr and IKs and the sympathetic nervous system. The sympathetic nervous system controls the 
rate and force of contraction of the heart. Stimulation of the sympathetic nervous system results 
in a higher heart rate and shorter action potential seen as the QT-interval on the surface ECG 
(Rockman et al 2002). Action potential duration shortens even more than would be expected 
solely on the basis of RR-interval shortening. IKs is considered responsible for this shortening 
of action potential duration and is influenced by increases in adrenergic tone (Kurokawa et al 
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2003). The mechanism of adrenergic activation of the KCNQ1/KCNE1 and KCNH2/KCNE2 
protein complexes involves a G-protein-mediated increase of cyclic adenosine monophosphate, 
followed by activation of protein kinase A and phosphorylation of the channel complexes 
(Roden et al 2002). IKs is considered to be more sensitive to adrenergic stimulation(Cheng et al 
1999).
As a result of increased sympathetic nervous system tone, IKs current amplitude is increased, 
deactivation is slowed and the channel activation curve is shifted resulting in earlier activation, 
all changes expected to increase current during myocardial repolarization. Due to the slow 
deactivation of IKs under these conditions, IKs accumulates in a beat-to-beat fashion (Lu et al 
2001, Rocchetti et al 2001, Terrenoire et al 2005). For this reason, the relative lack of IKs
during sympathetic stimulation can lead to arrhythmia in LQT1 patients. This adrenergic 
regulation is a complex process involving not only the KCNQ1 protein. KCNQ1 requires the 
KCNE1 subunit (Kurokawa et al 2001, Kurokawa et al 2003), protein phosphatase 1, protein 
kinase A and the protein yotiao for catecholaminergic regulation. Intriguingly, the mutation 
G589D (KCNQ1-Fin) disrupts the binding site of yotiao leading to lack of ?1-adrenergic 
mediated signalling via this mutant channel (Marx et al 2002). When KCNQ1 is complexed 
together with KCNE1 and the targeting protein yotiao, the effect of cyclic adenosine 
monophosphate activation is an increase in current.  
However, views differing from the one described above exist. In isolated rabbit and dog 
ventricular myocytes complete pharmacological block of IKs did not prolong action potential 
duration (APD) (Varro et al 2000, Lengyel et al 2001). This finding was supported by findings 
in undiseased human ventricular myocytes (Iost 2005). However, the lack of effect of IKs block 
on normal human APD was documented during absence of sympathetic stimulation. The role 
of IKs has been debated to be to that of APD abbreviation following premature beats or during 
bradycardia during elevated sympathetic tone. In spite of these differing views on the role of 
IKs, it does, however, seem, that sympathetic stimulation increases IKs.
Although the evidence on the effects of increased sympathetic tone on IKr is conflicting it 
appears that the major effect is a decrease in current. The amino acid sequence of KCNH2 has 
four putative protein kinase A phosphorylation sites and a regulatory cyclic nucleotide binding 
domain in the cytoplasmic end of the channel (Tseng 2001). In in vitro studies it has been 
noted that IKr in guinea-pig ventricular myocytes is increased significantly by phosphorylation 
of the channel complex by protein kinase A or protein kinase A. The mechanism involved was 
a reduction in C-type inactivation (Heath et al 2000, Kiehn et al 2000). Contrary to this, in 
KCNH2-transfected mammalian cells, the addition of a cyclic adenosine monophosphate 
analog shifted the activation of IKr to more depolarized potentials and the accelerated 
deactivation (Cui et al 2000). The removal of all four protein kinase A phosphorylation sites 
prevented this effect (Thomas et al 1999, Cui et al 2000). Evidently, the ?-adrenergic 
stimulation of IKr is quite complex, involving channel phosphorylation and direct cyclic 
adenosine monophosphate effects. In spite of these studies, it is not completely clear how 
native human IKr channels are modulated by sympathetic nervous system stimulation (Iost et al 
1998).
Heath and Terrar’s report stated that current was increased while almost all other reports 
claimed that current was decreased (Kiehn et al 1998, Cui et al 2000, Kiehn et al 2000, Karle et 
al 2002, Thomas et al 2004). The explanation can be in methodology, because Heath and 
Terrar used the switched electrode voltage clamp (SEVC) technique in order to minimize 
damage to the cytoplasmic machinery and activated ?-receptors with modest concentrations of 
isoprenaline (Heath and Terrar 2000). As a result of this, C-type inactivation was decreased 
and correspondingly, current increased. In several other experimental studies, IKr was 
diminished in a PKA- and cAMP-dependent fashion (Kiehn et al 1998, Cui et al 2000, Kiehn et 
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al 2000, Karle et al 2002). However, the main effect of ?-adrenergic stimulation appears to be 
is PKA-dependent phosphorylation and direct binding of cAMP to the channel protein 
(Thomas et al 2004). In view of the present data, ?-adrenergic regulation of IKr seems to be a 
complex process and it would be an oversimplification to state that it would either be increased 
or decreased due to ?-adrenergic stimulation. However, as LQT2 patients tend to experience 
arrhythmia as a result of sudden increases in adrenergic tone, it is very likely, that in humans, 
IKr is indeed decreased as a result of  ?-adrenergic stimulation (Thomas et al 2004). However, 
the additive effect of RR-interval shortening as heart rate increases on the amount of open and 
conducting channels due to incomplete deactivation possibly offsets this decrease due to 
increased adrenergic tone.  
Polymorphisms in the ß1-adrenoceptor. Of genes possibly increasing predisposition to 
arrhythmia in LQTS patients, β1-adrenoceptor genes are likely candidates because they are 
important mediators of adrenergic tone exerting a chronotropic and inotropic influence on the 
cardiomyocyte. In the heart, the  β1-adrenoceptor accounts for 75-80% of all cardiac ?-
receptors (Rockman et al 2002).  
Figure 6. The β1-adrenoceptor. The ?1-adrenoceptor is a seven transmembrane spanning G-
protein coupled receptor. The S49R polymorphism is intracellular, while the G389R 
polymorphism is extracellular and exists close to the G-protein-coupling domain.  
In 1999 two common polymorphisms were reported in the β1-adrenoceptor protein at amino 
acids 49 and 389 (serine substituted for glycine and arginine substituted for glycine, 
respectively) (Maqbool et al 1999). The latter polymorphism has been reported to be a gain of 
function polymorphism with allele frequencies of 0.26 and 0.74. Basal adenylyl cyclase levels 
for the two receptor subtypes are similar, but isoproterenol-stimulated levels are 60% higher 
for the R389 receptor than the G389 receptor in vitro (Mason et al 1999). In right atrial 
appendages, greater inotropic and cyclic AMP responses evoked by norepinephrine have been 
reported for the R389 variant of the β1-adrenoceptor (Sandilands et al 2003). Contradictory to 
this, in a study by Molenaar and co-workers, the cardiostimulant effects of norepinephrine as 
determined by change in contractile force on both the R389/G389 and S49/G49 receptor 
variants were found to be conserved (Molenaar et al 2002). When a modified dobutamine 
stress echocardiography protocol was carried out on patients homozygous for either the R389 
or G389, it was, however noted that, ?1-adrenergic genotype determines contractile 
responsiveness to catecholamines (La Rosee et al 2004).  
The S49G polymorphism, on the other hand, has not been found to alter receptor performance. 
In a recent study, the G49 receptor showed greater long-term agonist-promoted downregulation 
than the S49 receptor (Rathz et al 2002). The serine (S) and glycine (G) allele frequencies have 
been reported to be 0.87 and 0.13, respectively. The S49G and R389G mutations were not 
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found to be associated with symptomaticity in a group of acquired LQTS patients (Yang et al 
2002). In genetically proven LQTS patients, the relation between symptomaticity and β-
adrenoceptor genotype has not been studied so far. In other diseases, the G389 allele has been 
found to have a suppressive effect on ventricular tachycardia in dilated cardiomyopathy and the 
R389 allele (Iwai et al 2002), on the other hand, a detrimental effect on the progression of heart 
failure (Mialet Perez et al 2003). These data suggest that this polymorphism has at least some 
independent effects in these various processes and diseases.  
The S49G polymorphism has been suggested to impact a beneficial effect in chronic heart 
failure due to its cellular phenotype (Rathz et al 2002). It is unlikely that any ?-adrenergic
polymorphism on its own would have a large role in predisposition to different pathological 
states (Buscher et al 2001).  What remains to be seen is what is the role of combinations of 
polymorphisms in single genes or between two or more genes in human cardiovascular disease. 
An example this type of observation is the ?1-adrenoceptor R389 genotype acting together 
with an ?2c-adrenergic polymorphism which has been shown to have a an impact on the risk of 
heart failure in blacks (Small et al 2002). ?-adrenergic polymorphisms have been recently 
reviewed and due to the presumably subtle effects ?-adrenergic polymorphisms, their role in 
other diseases and states remains debated (Leineweber et al 2003, Small et al 2003). 
Drug block of IKr: the acquired long QT syndrome. Numerous drugs block IKr (Redfern et al 
2003, Tamargo et al 2004, Sanguinetti et al 2005). For an up-to-date list, see 
http://www.qtdrugs.org/medical-pros/drug-lists/drug-lists.htm. Most drugs are relatively 
selective for the KCNH2 channel, while others also block other cardiac ion channels (Roy et al 
1996). This non-selectivity of blocking primarily channels other than IKr channels can offset 
the QT-interval prolonging effect of these non-specific IKr blockers and make them potentially 
less harmful. However, due to the postulated large repolarization reserve in the human heart 
due to an excess of IK (IKr and IKs), larger plasma concentrations of blocking drug are required 
for arrhythmia to occur than could be assumed on the basis of in vitro studies (Kivisto et al 
1999, Roden et al 2006). It is not known whether this is due to increased expression of KCNH2 
due to drug block or to other factors. Drug block of defective KCNH2 channels increases 
channel expression in vitro, i.e. rescues the defective channel proteins to the cell membrane 
(Kaufman et al 2003). It has been postulated that absence of action potential triangulation, 
instability or use-dependence of drug block makes a drug less proarrhythmic and possibly even 
antiarrhythmic (Hondeghem et al 2001, Hondeghem et al 2001). An example of this is 
amiodarone (Belardinelli et al 2003).
Use-dependence of drug block means that at high heart rates, a substantial proportion of 
KCNH2 channels are blocked. Drug block can also show reverse use-dependence which means 
that at high heart rates, there is less block of IKr. Examples of the former are the gastrointestinal 
prokinetic cisapride and the antifungal terfenadine(Roy et al 1996, Walker et al 1999), while of 
the latter, dofetilide, a class III antiarrhythmic (Mounsey et al 2000).  
Polymorphisms in KCNH2. Numerous polymorphisms have been found in KCNH2 and other 
LQTS genes (Larsen et al 2001, Aydin et al 2005, Gouas et al 2005). The KCNH2 K897T 
polymorphism was first described by Laitinen and colleagues (Laitinen et al 2000). It is 
situated in the C-terminus of the protein which has been associated with decreased protein 
expression and an absence of the mature, glycosylated form of KCNH2 (Zhou et al 1998, 
Furutani et al 1999, Thomas et al 1999, Ficker et al 2000, Kagan et al 2000, Ficker et al 2002, 
Kuperschmidt et al 2002). Protein trafficking defects reduce delivery of potassium channels to 
the cell membrane (Zhou et al 1998, Petrecca et al 1996, Furutani et al 1999, Thomas et al 
1999, Ficker et al 2000, Kagan et al 2000, Ficker et al 2002, Kuperschmidt et al 2002). After a 
protein is synthesized in the ribosome, many tightly regulated processes must occur before the 
protein, in this case a potassium channel, exists and functions on the cell membrane. First, the 
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protein is folded into the proper tertiary structure, then assembled with other proteins, cleaved 
into a mature form, transported to other intracellular location and sorted for its final 
destination. Then, after serving its purpose, it must be targeted for degradation (Delisle et al 
2004). Wild-type and mutant channels with normal trafficking can be distinguished from these 
channels, because these trafficking-deficient channels are only minimally present on the cell 
membrane. It has been postulated that the majority of KCNH2 point mutations lead to 
trafficking deficient proteins (Anderson et al 2006). 
Numerous phenotypic effects have been attributed to the K897T polymorphism. In a 
population of middle-aged Finnish women, it was postulated that the common K897T 
polymorphism somewhat alters cardiac repolarization in middle-aged Finnish women (Pietilä 
et al 2002). After adjustment for echocardiographic and various laboratory variables, the 
KCNH2 K897T polymorphism remained an independent predictor of QTcmax and the Tpeak-
Tend intervals in females but not males. In a report from the same group, subjects with the 
K897T or T897T genotype showed increased dyssynchrony between depolarization and 
repolarization than those with the K897K genotype (Linna 2006). Also, in a population of 
healthy individuals, the T897 was associated with a shorter QT interval (Gouas et al 2005).
In another study, the K897T polymorphism was found not to have caused or increased risk of 
acquired LQTS in a population of otherwise healthy individuals (Yang et al 2002). Neither did 
it alter channel performance in oocytes or expression in mammalian cells (Scherer et al 2002). 
However, in the study in question, deactivation and inactivation time constants were analyzed 
at only one voltage and using a single time constant, not two, and in oocytes, not mammalian 
cells, which can leave subtle differences in channel characteristics uncovered (Seebohm et al 
2001). Two other studies investigated the same polymorphism, one finding a hyperpolarized 
shift in channel activation and faster activation and inactivation kinetics at specific voltages in 
HEK-293 (human embryonic kidney) cells (Bezzina et al 2003), the other finding that K897 
channels generated more current than other polymorphisms but less than the wild type (Anson 
et al 2004). The latter study, which also utilized HEK-293 cells also suggested that K897 
channels open at more negative voltages and inactivate and recover from inactivation faster 
than wild-type channels leading to more current during cardiac repolarization. The latest report 
on the K897T polymorphism suggested that it modifies the clinical expression of a latent 
LQT2 mutation (A1116V) by IKr current(Crotti et al 2005). The small decreases in current 
observed for K897T in the heterozygous and homozygous states (K897T and T897T) do not 
cause LQTS but may accentuate the effects of a reduced repolarization reserve (Roden et al 
2006).
Other polymorphisms have also been suggested to induce a pathological influence on IKr
function and phenotype. One of these is the R1047L polymorphism, situated in the C-terminus 
of KCNH2 which has been suggested to play a part in the genesis of torsade des pointes. In 
electrophysiological experiments it exhibited slower activation and inactivation kinetics when 
expressed as a homo-oligomer in HEK-293 cells(Sun et al 2004). Another polymorphism, 
identified equally frequently in controls and patients who had experienced Torsade des pointes, 
the R784W polymorphism, was found to decrease, but not abolish, currents when KCNH2 was 
expressed in CHO cells (Yang et al 2002). 
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3. AIMS OF THE STUDY 
3.1 Study I 
The aim of the first study was to determine whether the reaction to intense mental and physical 
stress is different in LQT1, LQT2 and controls. This was accomplished by the study patients 
and controls undergoing a “mental stress” protocol and a graded exercise test while QT interval 
and other variables were recorded. 
3.2 Study II 
The purpose of the second study was to determine whether controls, LQT1 patients and LQT2 
patients could be differentiated on the basis of electrical restitution or monophasic action 
potential duration at different pacing rates and extrasystolic intervals during the control state, 
adrenaline and phenylephrine infusions. 
3.3 Study III 
It was studied whether the common Finnish KCNH2 polymorphism K897T has an influence on 
channel function or channel expression in a heterologous expression system and whether it 
influences cardiac repolarization at rest or during a maximal exercise test. 
3.4 Study IV 
The aim of the fourth study was to determine whether two common β1-adrenoceptor 
polymorphisms influence cardiac repolarization by utilising resting ECGs and maximal 
exercise tests in LQT1 patients, and to clarify whether these polymorphisms, either alone or 
acting together, influence symptomaticity in LQT1 patients. 
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4. MATERIALS AND METHODS 
4.1. Patients 
The study groups in study I were made up of 16 subjects with a proven KCNQ1 mutation, 14 
subjects with an established KCNH2 mutation and 14 healthy control individuals. The controls 
included 8 men and 6 women (aged 22 to 58 years), not taking any medication known to affect 
the functioning of the heart and they were without cardiac disease.   
Table 3. Baseline characteristics of patients in study I.  
 LQT1 LQT2 Controls 
Age,years  35±13     41±12 43±10 
Men/women  5/11  8/6  8/6  
Symptomatic/asymptomatic 0/16  0/14 0/14 
QTc interval (ms)   420±35  422±40  387±16 
The patient groups in study II were made up of 6 LQT1 patients, 5 LQT2 patients and 5 
controls. All LQTS patients had potassium channel mutations that had been shown previously 
to be disease-causing, as demonstrated by clinical, genetic and molecular evidence. All of the 
patients had had one or more arrhythmias, manifesting as syncope or documented torsade des 
pointes.
Table 4. Baseline characteristics of patients in study II. 
 LQT1 LQT2 Controls 
Age, years       42±29 26±13 46±7 
Men/women    2/4 2/3 1/4 
Symptomatic/asymptomatic     6/0   5/0   0/5 
Triggers for symptoms    
  Physical exercise/emotional arousal   5/1   1/4   
  QTc interval (ms) 528±83  527±72  404±17 
In study III, DNA samples and clinical data were available from 261 LQTS patients (120 males 
and 141 females, aged 3–89 years) who were established carriers of the founder mutation 
KCNQ1-Fin (G589D). Exercise electrocardiograms (ECGs) were measured from 53 carriers of 
the KCNQ1-Fin mutation (26 men, 27 women, aged 14–54 years). 
In study IV, DNA samples and clinical data were available from a total of 168 LQT1 patients 
older than 14 years. There were 61 male and 107 female patients. A total of 55 patients older 
than 14 years (29 males and 26 females) participated in the exercise tests. 
Table 5. Characteristics of patients in study IV.  
 Males Females 
Number of patients 49 88 
Mean age (range) 38±15 (16-74) 41±16 (16-78) 
Symptomatic/asymptomatic   16/33 45/43 
Mean resting QTc 469±46 485±34 
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4.2 Mental stress tests 
A mental stress test was used in study I. At the beginning of the study protocol, an intravenous 
cannula was inserted, and after 30 minutes of rest in the supine position, a resting 12-lead 
electrocardiogram (ECG) was taken followed by starting of continuous ECG monitoring. After 
standardized instructions provided by the study physician, the subjects performed a serial 
subtraction test, the Stroop color-word test and a serial addition test in a sitting position (Stroop 
1935). These tests were performed back-to-back with no pauses in between except for 
instructions from the study physician. Blood samples for measurement of serum potassium and 
plasma catecholamine levels were taken after 30 minutes of rest in the supine position before 
mental stress and at the maximal heart rate achieved during mental stress.  
4.3 Exercise stress tests 
Exercise stress tests were used in studies I, III and IV. In study I, when patients’ heart rates and 
blood pressures had returned to resting values after 5-10 minutes of rest in the supine position 
after mental stress testing, a modified maximal bicycle ergometer test was performed. In 
studies II and IV no mental stress test was performed and the bicycle ergometer test was 
continued until exhaustion. The primary workload was 30W and it was increased at one minute 
intervals by 15W.  
4.4 Assessment of QT intervals 
In study I, QT-intervals were measured at the maximum heart rate observed during mental 
stress and at a corresponding heart rate during exercise stress. In studies II and IV, continuous 
ECG monitoring was used during the exercise protocol and during recovery. In addition to this, 
resting ECGs were obtained.
In studies I, II and IV, the QT-interval was measured from the onset of the QRS complex to the 
end of the T-wave. The end of the QT-interval was defined as the intersection of a tangent to 
the steepest downslope of the dominant repolarization wave with the isoelectric line. QT-
intervals at rest were measured from two consecutive QT-intervals at a steady heart rate 
measured from four RR-intervals. QT-intervals at mental and exercise stress were measured 
from four consecutive QT-intervals at this steady heart rate. QTc was determined according to 
Fridericia’s formula (QTcf) (Fridericia 1920). In order to evaluate QT adaptation to heart rate 
changes in patients and controls during mental and exercise stress, ΔQT/ΔHR values were also 
calculated by plotting change in QT duration against corresponding change in heart rate 
(Viitasalo et al 1996, Swan et al 1998, Swan et al 1999).  
4.5 Clinical electrophysiology 
The electrophysiological test was performed to patients who had experienced symptoms which 
raised the possibility of an arrhythmic disorder. At the time these tests were performed, the 
diagnoses of these patients were still open and no LQTS-mutations had so far been found in the 
patients.  The controls, on the other hand, underwent an electrophysiologic test to assess the 
result of a previous atrioventricular accessory pathway operation.  
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Duration of monophasic action potentials (MAPs) at 50% (MAP50) and 90% (MAP90) levels or 
repolarization were recorded from the right interventricular septum while standard 12-lead 
ECG was monitored. Blood pressure was measured using a femoral artery cannula. 
Monophasic action potentials were plotted against the RR-interval for statistical analysis. 
Durations of MAPs at 90% levels or repolarization were calculated by adding to the durations 
of MAPs at 100% levels of repolarization. Diastolic intervals were determined by subtracting 
the MAP100 from the S1-S2 interval. The variables described above were measured at baseline 
and stable conditions during epinephrine and phenylephrine infusion. For safety reasons we 
limited epinephrine infusion at a target rate of 0.05 ?g/kg of body weight/minute, which was 
reached stepwise while arrhythmias were carefully monitored. A phenylephrine infusion rate of 
1–2 g/kg of body weight/min was chosen to increase systolic arterial pressure by at least 30 
mmHg. When stable conditions were achieved during epinephrine and phenylephrine infusion, 
the pacing protocol was performed. MAP50 and MAP90 were used because they were deemed 
best in quantifying triangulation of the action potential. The observers were blinded to the 
patients’ genotypes at all times.  
4.6 In vitro studies 
In study II, all measurements of whole-cell currents were performed at room temperature (22-
24˚C) using an EPC-9 amplifier and Pulse/Pulsefit software. The extracellular solution 
contained 150 mmol/l NaCl, 5.4 mmol/l KCl, 1.8 mmol/l CaCl2, 1 mmol/l MgCl2, and 5 
mmol/l HEPES. The recording pipettes were filled with a solution containing 150 mmol/l KCl, 
2 mmol/l MgCl2, and 5 mmol/l Bapta and 10 mmol/l HEPES. Recordings were performed 
approximately 48 hours after transfection. Input resistances of all cells were over 100 M? and 
patch pipette resistances were 2-3 M?. The series resistance was compensated in all 
experiments to ?70%. All electrophysiological recordings were performed on transiently 
transfected HEK-293 cells. The half-maximal voltages (V1/2) and the slope factors (k) of 
activation and inactivation were estimated by fitting a Boltzmann equation to the data. The 
time constants of inactivation and recovery from inactivation were determined by fitting a 
single exponential while the deactivation time course was determined by fitting a double 
exponential.
Forskolin, a adenylyl cyclase activator used to increase levels of cAMP, was dissolved in 
DMSO and perfused into the cell bath in the extracellular solution at a concentration of 10 
mmol/l. The final DMSO concentration was under 0.1% in all experiments and the control 
solution contained a similar concentration of DMSO with no effect on channel performance. 
Preparation of membrane protein fractions and Western blotting experiments were performed 
as described previously (Southern 2000). Membrane proteins were subjected to SDS-
polyacrylamide gel electrophoresis and incubated with 1:10000 diluted KCNH2-antiserum 
(Alomone labs, Jerusalem, Israel) at room temperature overnight. The antibody was detected 
with an ECL detection kit (Amersham Pharmacia Biotech, UK).  
4.7 Genotypings of LQTS genes 
The LQTS mutations were determined by polymerase chain reaction and restriction enzyme 
genotyping as described elsewhere (Piippo 2000a, Piippo 2000b, Laitinen 2000, Fodstad 2004). 
Analysis of the K897T polymorphism was performed by primer induced restriction analysis 
(PIRA) using a new reverse primer 5’-TCCCCTCCACCGCCTCACGC-3’. The resulting 
fragments were separated by electrophoresis on a polyacrylamide gel.  
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4.8 Genotypings of ?-adrenergic receptor genes 
DNA was isolated from venous blood samples using standard techniques. DNA was amplified 
by polymerase chain reaction (PCR). The PCR primers for assay of the R389G polymorphism 
were 5’-TGGGCTTCGAGTTCACCTGCTATC-3’ (anti-sense) and 5’- 
CGCTCTGCTGGCTGC- CCTTCTTCC-3’ (sense), resulting in a 564 bp fragment. Genotype 
was determined by cleavage of the PCR products with Bcg I (New England Biolabs, USA). 
The non-digested allele representing G389 remains as a single 530 bp fragment while the 
digested allele R389, designated as the wild type, is cleaved into fragments of 342, 154 and 34 
bp (Maqbool et al 1999). For analysis of the Ser49Gly polymorphism, the primers were 5’-
GGCGAGGTGATGGCGAGGTAGC-3’ (antisense) and 5’-CCGGGCTTCTGGGGTGTTCC-
3’ (sense), yielding a fragment of 463 bp in size. Genotype was determined by restricting the 
fragments with the enzyme Eco0109 (New England Biolabs, USA). The non-digested allele 
representing G49 remains as a single 463 bp fragment while the digested allele S49, designated 
as the wild type, is cleaved into fragments of 344 and 219 bp (Maqbool et al 1999).
In both cases, analysis of fragment sizes took place by ethidium bromide staining and 
electrophoresis in a 2% polyacrylamide gel. Because the G49 and G389 genotypes were 
infrequent, they were pooled with the heterozygous genotypes S49G and R389G, respectively. 
4.9 Statistics 
In study I, for analysis of differences between groups, analysis of variance and Mann-Whitney 
tests were used as well as Student’s independent means t test. Spearman’s correlation 
coefficient test was used to assess correlations between variables.  
In study II, the chi-square test was used to study dichotomous variables while statistical 
comparisons between groups were performed by analysis of variance (ANOVA). If significant 
effects were indicated, a Student’s t-test was used to evaluate the significance of differences 
between means. Generalized linear models were constructed to study repeated measures. A 
repeated measures ANOVA was used to compare differences between the groups. 
In study III, a series of generalized linear models were generated to detect differences in MAPd 
length between the two patient groups during atrioventricular sequential pacing.
In study IV, to characterize the effects of the two polymorphisms on the duration of cardiac 
repolarisation and symptomaticity in LQT1 patients, dichotomous variables were compared 
using the chi-square test and continuous variables using the t-test. Group data are expressed as 
frequencies or mean±SD. Due to the rarity of the G49G and G389G genotypes, they were 
pooled with the heterozygotes (R389G and S49G) for the statistical analyses. A general linear 
model for repeated measurements was used for dependent variables to estimate the effect of the 
putative factors on cardiac repolarisation during and after exercise (between and within main 
effects) (Miettinen 1974). Within subjects main effects were assessed using the Huynh-Feldt 
test. In these analyses, the cases under 15 years were excluded from the analyses, because 
pubertal status is known to affect the QT-interval. In order to test for interactions between the 
two β-1-adrenergic receptor polymorphisms, we used logistic regression methods to model the 
effect of each genotype and their interaction on the risk of arrhythmia and to control for 
confounding factors (sex and QTc-interval). Odds ratios with 95% confidence intervals were 
calculated. In the statistical modeling, all two-way and three-way interactions were tested, and 
an interaction term was included in the model if it reached statistical significance.  
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In all studies, a p<0.05 was deemed to indicate statistical significance and SPSS 11.0 (SPSS 
Inc, Chicago, Illinois, USA) was used for data analysis. 
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5. RESULTS AND DISCUSSION 
5.1. Cardiovascular changes and QT interval dynamics in response 
to mental and physical stress 
A total of 44 individuals (16 patients with type I LQTS, 14 with type 2 LQTS and 14 healthy 
controls) underwent a protocol involving three types of mental stress test and a submaximal 
exercise stress test. There were no significant differences in the resting or maximal heart rates 
achieved during the mental stress tests between the two groups of LQTS patients and the 
control group. Heart rate responses from rest to exercise stress were significant in all three 
subject groups (p<0.001). While the mean heart rate changes from rest to mental stress were 
not significantly different in the LQT1, the LQT2 and the control group, subjects showed 
pronounced interindividual differences in reactivity to mental stress.  
Serum potassium concentrations were not increased by mental stress in any of the groups 
studied, whereas physical exercise resulted in a significant (p<0.05) increase in serum 
potassium concentrations in all three groups.  
Baseline plasma epinephrine and norepinephrine concentrations were similar in the three study 
groups. Whether assessed between rest and mental stress or between rest and physical stress, 
there was a highly significant (p<0.001), approximately 2- to 2.5-fold increase in both plasma 
epinephrine and norepinephrine concentrations in all three subject groups.
Figure 7. Plasma noradrenaline, plasma adrenaline, serum potassium, heart rate, QT-interval, 
and QT-interval adjusted according to Fridericia's formula (QTcf) in controls, patients with 
long QT syndrome type 1 (LQT1), and patients with long QT syndrome type 2 (LQT2) at rest 
(blank), and during mental stress (light grey) and exercise (dark grey). 
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As expected, the LQT1 and LQT2 patients had longer QT intervals at rest and during mental 
stress and exercise stress compared with control subjects (all p<0.001). In healthy controls, 
shortening of the QT interval from rest to exercise (?QT) was more pronounced (-47 ms) than 
the corresponding shortening of the QT interval from rest to mental stress (-29 ms, p<0.01). In 
contrast, the QT interval response to exercise stress did not differ from that during mental 
stress in either LQT1 or LQT2 patients. When data at rest and during exercise were compared, 
changes in serum potassium concentration from rest to exercise were inversely correlated with 
changes in QT intervals in healthy controls, but not in LQT1 and LQT2 patients. No such 
correlation was found between changes in serum potassium concentrations associated with 
mental stress and ?QT values in any subject group.
This study described experimental conditions under which the effects of mental and physical 
stress on QT dynamics can be investigated. The effects of these two types of stressors on the 
QT interval were compared at similar heart rates. The clear increases in serum potassium 
concentrations during the modified bicycle ergometer test probably resulted from release of 
potassium ions from contracting skeletal muscles and reflects a considerable intensity of 
exercise (Lindinger et al 1995). The adequacy of the design in causing severe mental stress is 
further supported by the finding that catecholamine responses during the mental stress test 
were similar in magnitude to those during exercise. Mental stress brought about mean heart 
rate increases of 31-34 beats/min in the three subject groups. There are no previous data on the 
effect of mental stress on QT dynamics in LQTS. Because of ethical objections, only 
asymptomatic gene carriers were studied. A significant shortening of QT interval in response to 
mental stress was observed in healthy controls as well as in LQT1 and LQT2 patients, but QT 
interval shortening in response to exercise stress was greater in controls. In the latter patients, 
these changes in QT interval were significant when the calculations were based on ?QT 
intervals, percentages of resting QT intervals or ?QT intervals adjusted to ?HR.
KCNQ1 coassembles with KCNE1 and the resulting potassium channel is responsible for the 
cardiac slowly activated inward rectifier potassium current (IKs)(Barhanin et al 1996, 
Sanguinetti et al 1996), while KCNH2, which possibly coassembles with KCNE2, accounts for 
the rapidly activated current (IKr)(Curran et al 1995, Abbott et al 1999). As these two currents 
show significant electrophysiological differences, it was unexpected that no significant 
differences in the responses to mental or exercise stress were seen between LQT1 and LQT2 
patients. The amount of IKr has been shown to increase concomitantly with increases in 
extracellular potassium in (Scamps et al 1989, Yang et al 1997), even though potassium flow 
from the cardiac myocyte during repolarisation is outward and increased extracellular 
potassium should decrease the driving force for outward currents through IKr and IKs. It can be 
speculated that wild-type KCNQ1 + KCNE1 and KCNH2 (+KCNE2) channels are more 
sensitive to extracellular potassium during exercise than mutated channels or that LQTS 
patients lack sufficient repolarization reserve due to defective channels and action potential 
shortening during exercise is not possible(Roden et al 1998).
5.2. Effects of epinephrine and phenylephrine on right ventricular 
monophasic action potentials in LQT1 and LQT2 
Endocardial monophasic action potentials from the right interventricular septum were recorded 
in six symptomatic LQT1 and five LQT2 patients as well as five control patients, both at 
baseline and during epinephrine and phenylephrine infusions. Systolic blood pressure was not 
influenced by epinephrine, but phenylephrine increased it in the three study groups. 
Epinephrine tended to shorten, whereas phenylephrine tended to increase sinus cycle lengths in 
the three groups. MAP90 durations at different cycle lengths during baseline and during 
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adrenergic interventions in the study groups are depicted in Figure 8. During baseline, the 
linear relations between MAP90 and cycle length in the study groups gave the mean slope 
values (±SE) 0.25 (±0.07) in LQT1, 0.29 (±0.07) in LQT2 and 0.17 (±0.02) in controls. During 
epinephrine, the corresponding slopes were 0.45 (±0.07), 0.21 (±0.06) and 0.14 (±0.02), 
respectively (p<0.01 between LQT1 and controls). The average MAP50-to-MAP90 duration in 
LQT1, LQT2 and the control groups were 52±10, 58±11 and 44±7 ms, respectively. Both 
LQT1 and LQT2 groups exhibited longer average MAP50-to-MAP90 durations than the controls 
(p<0.01 between LQT1 and controls, p<0.001 between LQT2 and controls). During 
epinephrine, the MAP50-to-MAP90 duration showed a high correlation with the cycle length in 
the LQT1 group (r=0.63, p<0.01). Compared with the same paced cycle lengths during the 
interventions, epinephrine prolonged the baseline MAP50-to-MAP90 duration in the LQT1 
group from 53±11 to 71±14 ms (p<0.01) while no such prolongation was seen in the LQT2 or 
control groups. Phenylephrine did not change MAP50-to-MAP90 duration in any group.
Restitution kinetics were determined during atrioventricular sequential pacing, using the 
approach of empirical restitution rate. At the atrioventricular paced rate of 600 ms, the 
empirical restitution coefficients were 0.12±0.04 in LQT1 patients, 0.14±0.08 in LQT2 patients 
and 0.05±0.03 in the control patients. Compared with the control patients, restitution 
coefficients were greater both in LQT1 patients (p<0.01) and LQT2 patients (p<0.05). At the 
cycle length of 400 ms, LQT1 patients showed even greater restitution coefficients, with a 
mean value of 20±0.05 (p<0.05 compared with the cycle length of 600 ms). LQT2 patients as 
well as control patients showed similar restitution coefficient values at both cycle lengths. At 
the cycle length of  600 ms, epinephrine increased the restitution coefficient to 0.22±0.09 
among LQT1 patients. In contrast, LQT2 patients or control subjects did not increase the 
restitution coefficients during epinephrine infusion. Phenylephrine did not change restitution 
coefficients in any of the patient groups. 
Figure 8. Restitution curves against diastolic intervals in LQT1 (diamonds), in LQT2 (squares), 
and in control subjects (triangles) at baseline (panel A) and during epinephrine infusion (panel 
B); the atrioventricular paced cycle length is 400 ms. Interpolated from graphs shown in panel 
B, the restitution rates (Rk) in LQT1 and in LQT2 patient groups, expressed as ?MAP100/?DI,
are >1 at very short diastolic intervals (panel C). 
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These results demonstrate that LQT1 patients exhibit more rapid MAP shortening during 
premature depolarizations at high heart rates and during sympathetic stimulation by 
epinephrine. In addition, epinephrine increases the triangulation as defined by a decelerated 
return to resting potential during repolarization and the rate dependence of the ventricular MAP 
in LQT1, thus differentiating LQT1 and LQT2. Phenylephrine does not change MAP behavior 
emphasizing the importance of the ?-adrenergic stimulation in arrhythmia in LQT1. The effects 
of catecholamines on repolarization kinetics have been investigated in a few previous studies, 
using mostly clinically diagnosed LQTS patients. Hirao et al observed that epinephrine 
prolonged MAP90 rather constantly at heart rates from 100 to 140 beats/min (Hirao et al 1996). 
Shimizu and collaborators reported that in addition to MAP90 prolongation, epinephrine 
induced early afterdepolarizations in both clinically diagnosed LQTS patients and genotyped 
LQT1 patients (Shimizu et al 1995, Shimizu et al 1998, Volders et al 2000). Epinephrine has 
been shown to prolong QTc intervals more in LQT1 than in LQT2 patients (Tanabe et al 2001, 
Ackerman et al 2002, Noda et al 2002). The present study adds to the previous clinical 
knowledge of adrenergic effects on the arrhythmogeneity in LQTS by comparing the detailed 
MAP behavior under ?- and ?-adrenergic stimulation in molecularly defined LQT1 and LQT2 
patients.
The IKr current is larger than the IKs current (Viswanathan et al 1999). Blocking the IKr current, 
as in an LQT2 model, is therefore expected to prolong phase 3 repolarization and cause 
triangulation of the action potential (lHondeghem et al 2001). In fact, we noticed a prolonged 
MAP50-to-MAP90 duration in LQT2 patients. Also, LQT1 patients showed longer MAP50-to-
MAP90 durations than control subjects and epinephrine increased this difference.  
Incomplete deactivation and accumulation of the IKs potassium current at fast heart rates 
together with an increase of the outward INaCa current play a role in rate adaptation of APD 
(Viswanathan et al 1999). Shimizu and Antzelevitch observed steeper APD-rate relation 
compared with a control system with unaffected QT dynamics, and an experimental LQT2 
model showed likewise a more pronounced APD-rate relation than a control system (Shimizu 
et al 1998). The present study indicates that both LQT1 and LQT2 patients show a trend to 
steeper MAP-rate relations compared with controls at baseline. Under epinephrine the 
differences between LQT1 and control groups became clearly distinct (Figure 9). Therefore, an 
important finding of the present study was that both LQT1 and LQT2 patients exhibit 
prolonged MAP50-to-MAP90 duration compared with controls at baseline. This prolongation, 
termed triangulation, has been associated with the development of early afterdepolarizations 
and proarrhythmia in animal models (Hondeghem et al 2001). Epinephrine increased the 
triangulation of MAP in LQT1 patients in a cycle length-dependent fashion, consistent with the 
clinical finding that most LQT1 patients experience life-threatening arrhythmias in 
adrenergically stimulated situations.  
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Figure 9. Triangulation of action potential due to epinephrine infusion. Even though action 
potential amplitude is constant, the downsloping phase 3 is longer in duration in LQT1 patients 
during epinephrine infusion.
Due to the differences between IKr and IKs, the action potential is triangulated already at rest in 
LQT2, while epinephrine infusion triangulates the action potential in LQT1 during atrial 
pacing. There may be several reasons for this. First of all, at rest, and during “basal” 
sympathetic nervous system tone, the most important function of IKr is to act as a sieve for K+
ions and to prevent EADs and variations in diastolic intervals and action potential duration. 
When IKr does not function properly, as in LQT2, sudden surges in sympathetic nervous system 
tone can lead to arrhythmia because there is not enough IKr to fall back on. This surplus of IKr
has been called the repolarization reserve (Roden et al 1998). If repolarization reserve is 
lacking, IKs does not have time to react to the ?- and ?-adrenergic stimulation which would in a 
couple of seconds, increase IKs. This is in accordance with the mode of onset of arrhythmia in 
LQT2. It is possible that this triangulation at rest in LQT2 is due to the proven lack of IKr. The 
explanation offered above also explains the triangulation of the APD in LQT1 patients during 
epinephrine infusion, as they lack IKs which is needed for APD shortening during exercise. 
Another possible reason for triangulation at rest in LQT2 and at exercise in LQT1 is that IKs
and IKr exhibit maximal repolarizing current at different stages of the action potential. IKs is 
maximal clearly earlier than IKr, increasing triangulation in LQT2. This supports earlier in vitro 
and simulation studies that suggested block of IKr is expected to cause action potential 
triangulation and proarrhythmia (Hondeghem 2001,Hondeghem et al 2001).  
The electrical activity and contractility of cardiac muscle fibers is rate dependent. Rate-
dependent alterations in action potential duration may be different in distinct myocardial layers 
increasing the inhomogeneity of refractoriness and contribute to the genesis of reentrant 
ventricular tachyarrhythmias such as torsade des pointes. In cell models, the block of IKs
especially in the presence of adrenergic stimulation results in the development of abnormal 
repolarization and EADs (Shimizu et al 1991, Shimizu et al 1994, Volders et al 2000). The 
block of IKr, on the other hand, triangulates the action potential and induces EADs as well.
The action potential can be lengthened by prolongation of the phase 2 (the plateau phase) or 
phase 3 (the downsloping phase) or both (Nerbonne et al 2005). During phase 2 the 
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repolarizing currents are mainly due to activation of L-type Ca2+channels, slowly inactivating 
Na+ channels and the slow inward rectifying potassium current IKs, which proggressively 
activates during the plateau phase. During phase 3, the rapid delayed rectifier IKr activates 
while IKs slowly deactivates, making IKr the ion current largely responsible for phase 3 
repolarization (Nerbonne et al 2005). As a result, when IKr blockade or absence is present, the 
shape of the action potential becomes more triangular (Hondeghem et al 2001, Viitasalo et al 
2005). In recent studies it has been suggested that lengthening of the action potential, due to for 
example antiarrhythmic medication, is antiarrhythmic, but triangulation of the action potential 
with or without lengthening can be proarrhythmic (Hondeghem et al 2001, Hondeghem et al 
2001).
Triangulation and temporal instability of APD are proarrhythmic for several reasons. During an 
extended and triangulated phase 3 of the action potential, calcium or sodium channel 
reactivation can lead to EADs which in turn can lead to arrhythmia. Also, conduction may be 
incompletely recovered or slowed due to inappropriate sodium currents and this may lead to re-
entry.
It is possible that in LQT2 patients, where the channel dysfunction is due to exceedingly fast 
deactivation, for example in the common KCNH2 L552S mutation, altering deactivation in 
favor of channel function could in part remove the repolarization abnormalities observed 
(Piippo et al 2000).
During epinephrine infusion, an exaggarated time course for APD restitution was observed in 
LQT1 and LQT2 patients. In both groups, the MAPD restitution slope was >1, that, according 
to the restitution hypothesis presented by Weiss (Weiss et al 2000), suggests increased risk of 
Torsade des pointes to degenerate into ventricular fibrillation at fast heart rates.
5.3. Electrophysiological and in vitro studies of the KCNH2 K897T 
polymorphism
The K897 and T897 isoforms of the KCNH2 channel were studied electrophysiologically in 
vitro. Depolarizing voltage steps followed by repolarization to -60 mV resulted in the T897 
isoform of KCNH2 displaying the characteristic inward rectification and subsequent large tail 
currents similar to those of the more common isoform K897. The variant 897T form of the 
KCNH2 channel exhibited a similar half-maximal activation voltage (V1/2) as the K897 form 
(-5.9±7.4 mV vs. -7.6±7.0mV). In the presence of forskolin, there was no significant difference 
in the V1/2 of K897 and T897 channels. The differences in deactivation and inactivation 
parameters between the two isoforms were comparable to those at baseline. The time course of 
current activation was investigated at +20 mV. The rate of activation was found to be similar 
for the two isoforms, but there was a difference in the rate of deactivation between them. Both 
the fast and the slow deactivation time constants were significantly slower for the T897 variant 
channels at -40 mV. At all the test voltages used from +40 mV to -20 mV the rate of 
inactivation was slower for the variant T897 channel than for K897 (all p<0.05). There was a 
shift in the voltage dependence with the variant T897 exhibiting a more negative V1/2 than the 
more common isoform, suggesting that there are fewer channels available for T897 at any 
given membrane potential. The maximum KCNH2 current was much larger in the cells 
expressing the K897 channel subunits than in those expressing the variant T897. The increased 
steady state inactivation is expected to result in a decrease in the available current, but this 
alone was hardly sufficient to explain the differences in current density observed between the 
isoforms.  
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The remaining difference could be due to a decreased expression of the T897 subunit in 
comparison to the K897 subunit, and/or to a change in the single channel properties. In HEK-
293 cells, the overall expression of the T897 isoform was much reduced when compared to that 
of the 897K isoform, as determined by Western blotting. The ratio of the membrane-associated 
form to the precursor form was reduced for the T897 variant, suggesting that the surface 
targeting of the T897 channel subunits was impaired. Although a difference in single channel 
properties between K897 and T897 cannot be excluded, the reduced surface expression of the 
T897 isoform together with the observed increase in activation is sufficient to explain the 
differences elicited by the two isoforms.  
The in vivo phenotypic effects of the T897 allele in a group of patients who were carriers of the 
KCNQ1-Fin mutation, a founder gene accounting for approximately 30% of all LQTS cases in 
Finland (Piippo et al 2000) were also determined. In this group of 261 LQTS patients, 47/153 
(31%), 22/89 (25%) and 3/19 (16%) of the patients with the genotypes K897K, K897T and 
T897T, respectively, were symptomatic having a history of syncope or documented cardiac 
arrhythmias. Patients with the K897 genotype and those with the genotypes K897T and T897 
showed very similar QT intervals during exercise and recovery. When the patients with 
prolonged QT intervals (QTc>440 ms) at rest (n=39) were considered separately, a significant 
KCNH2-genotype-dependent difference in the QT interval dynamics was noted. Resting QTc
intervals were similar in these two groups, being 469±5 in the K897K group and 477±5 in the 
K897T + T897T group. During exercise, patients with the K897T + T897T genotypes had 
longer QT-intervals than those with the K897K genotype, while no KCNH2-genotype-related 
difference was observed during the recovery period at any heart rate.
The present data show that KCNH2 T897 channels have biophysical properties in vitro which 
differ in respect to channel inactivation and deactivation from those of KCNH2 K897 channels 
and which are associated with clinical phenotype variation. T897 channels inactivate more 
slowly but show a higher degree of inactivation, an alteration that is expected to decrease 
channel function. It is also possible that changes in T897 inactivation properties can alter drug 
sensitivity (Suessbrich et al 1997, Ficker et al 1998). The decreased rate of inactivation 
accompanied with unaltered recovery from inactivation would predict that steady state 
inactivation should decrease, rather than increase as found here. Similar findings have, 
however, been reported for KCNH2 mutations in the S4 region (Nakajima et al 1998, Nakajima 
et al 1999).
5.4. Effects of the two common ?-adrenergic polymorphisms on 
phenotype in LQT1
The R389G polymorphism had a significant main effect on the QT-interval during exercise in 
LQT1 patients when the results were adjusted for sex (p<0.01), a finding similar to the one 
noted on the QTc-interval at rest. The estimated QT-interval was significantly longer 
throughout the exercise test in patients with the G389 + R389G ?1-adrenoceptor genotypes 
than in those with the more active genotype R389 (395 ms at 100 bpm to 345 ms at 150 bpm 
vs. 372 ms at 100 bpm to 315 ms at 150 bpm, respectively) (Figure 10). This effect was also 
independent of the S49G polymorphism. A similar effect was noted when Holter recordings 
from the same patients were analyzed (Figure 11).  
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Figure 10. QT-interval during exercise in R389R (Arg389Arg) subjects and R389G 
(Arg389Gly) + G389G (Gly389Gly) subjects during exercise and recovery. Due to the 
increased sympathetic nervous system tone during exercise, the QT-interval is shorter in 
R389R subjects than in R389G + G389G subjects. 
Figure 11. QT-intervals in R389R (Arg389Arg) and R389G (Arg389Gly) + G389G 
(Gly389Gly) patients during Holter recordings at heart rates 60 to 100. The same is evident as 
during exercise in Figure 10, QT-intervals are shorter in R389R subjects than in R389G and 
G389G subjects. 
Females tended to have more symptoms than males (50.0% vs 35.9%, p=0.08). Neither of the 
polymorphisms independently affected the frequency of symptoms: 49% of the patients with 
the genotypes G49G and S49G and 42% of the patients with S49 genotype were symptomatic. 
Forty-four percent of the patients with the G389 and R389G genotypes and 45% of the patients 
with the R389 genotype were symptomatic. Interestingly, when we utilized logistic regression 
methods, again, controlling for QTc and sex, to model the interaction of the two 
polymorphisms, the patients with both the genotypes presumed to be associated with more 
active receptor isoforms on the basis of in vitro studies (S49, R389) had a substantially 
increased risk for symptomaticity (p=0.029). 
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Table 5. Influence of S49S/R389R homozygosity on symptomaticity. Wald’s test was used to test for interaction. 
  Regression 
coefficient
Standard Error Wald Significance  Adjusted odds ratio for 
symptomaticity 
(95%CI) 
Sex -0.314 0.346 0.823 0.364 0.730 (0.370-1.440) 
Age -0.008 0.009 0.812 0.368 0.992 (0.974-1.010) 
QTc  0.013 0.004 9.740 0.002 1.013 (1.005-1.022) 
S49  -0.887 0.604 2.158 0.142 0.412 (0.126-1.345) 
R389 -1.418 0.599 5.610 0.018 0.242 (0.075-0.783) 
S49+R389    1.589 0.726 4.786 0.029 4.90 (1.180-20.347) 
      
The β1-adrenoceptor polymorphism R389G influences the QT-interval and thus, cardiac 
repolarization in patients with a KCNQ1 mutation shown to be deficient in adrenergic 
signalling (G589D) as well as in LQT1 patients with other disease-causing mutations. The 
more active β1-adrenoceptor altered the QT-interval in such a way that QT-intervals were 
shorter at baseline and during exercise.  
Compound homozygosity for the R389 and S49 receptors influenced symptomaticity 
substantially, indicating that carrying these two more active β1-adrenergic receptors carries an 
increased risk of symptomaticity for LQT1 patients. Further research will hopefully clarify 
whether the presence of these two alleles indeed confers an added risk of symptomaticity and 
how large is this added risk. It is possible that in the future, a group of polymorphisms in 
different genes, including ?1-adrenoceptor genes, can be evaluated to determine an individual’s 
risk of arrhythmia for example using a DNA chip technique.  
In summary, mental stress does not differentiate LQT1 and LQT2 patients as determined by 
QT-interval. Subtle genetic differences in the genetic makeup of LQT1 patients, such as the 
KCNH2 polymorphism K897T and the β1-adrenergic polymorphism G389R modify genotype 
as determined by QT-interval and symptomaticity. Also, restitution kinetics and action 
potential morphology response to epinephrine differentiates LQT1 patients from LQT2 
patients.
5.5 Limitations 
It has been shown in transmural recordings of monophasic action potentials in canines that 
although AP duration does not decrease, action potential amplitude decreases with time by up 
to 30% when measured from the subepicardium, the midwall and the subendocardium (Zhou et 
al 2002). However, if this was indeed a source of error in our study, it would be expected that 
the MAP50 to 90 ratio would be decreased in controls and LQT2 patients and not only LQT1 
patients as the AP flattens. This type of morphological change was not observed. Another 
source of error is the location of the catheter in the endocardium. IKr and IKs are expressed to 
different extents in the endocardium, the M-layer and the epicardium (Liu et al 1995). Another 
potential source of error is the short train of steady state pacing preceding the coupling interval, 
it is possible that a steady state was not achieved during the eight beat drive train. The presence 
of early afterdepolarizations as a source of error was discussed in the original article.  
There are also some technical issues related to reliable recordings of monophasic action 
potentials from the endocardium, such as instability of the contact of the electrode to the 
endocardium and artefacts caused by mechanical contractility of the heart. Furthermore the 
distance between the pacing and recording electrodes may potentially have influence on the 
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monophasic action potentials. All these factors may cause potential errors in the shape of the 
monophasic action potentials.
For safety reasons, the infusion of epinephrine was limited to 0.05 ?g/kg of body 
weight/minute. This increased heart rate by 9 to 23 beats per minute which is not much when 
compared to the increase in heart rate that occurs as a result of strenuous exercise or a powerful 
external stimulus. Another drawback of a steady infusion of epinephrine is the potential failure 
to see a possible arrhythmogenic triangulation of the action potential in LQT2 patients before 
the increase in adrenergic tone increases IKs to counter for the lack of IKr (Terrenoire et al 
2005).
In the future it would be interesting to know whether the results of a protocol performed in the 
second study would be different in asymptomatic versus symptomatic LQT1 and LQT2 
patients. Also, it would be interesting to see whether results would differ if LQT2 patients were 
paced and then a bolus of epinephrine was infused, would this induce a passing triangulation of 
the action potential as a sign of increased risk of arrhythmia. 
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6. CONCLUSIONS 
? During mental stress, the mean QT interval shortened to a similar extent in controls, LQT1 
patients and LQT2 patients. During exercise, the corresponding QT adaptation was more 
pronounced in healthy controls than in LQT1 or LQT2 patients.
? LQT1 and LQT2 could not be differentiated on the basis of heart rate or QT-interval 
response to physical stress and intense mental stress. LQTS patients, however, could be 
differentiated from controls. 
? During sympathetic stimulation by epinephrine, symptomatic LQT1 patients showed more 
pronounced monophasic action potential shortening during rapid pacing than LQT2 patients or 
controls.  
? In LQT1 patients, infused epinephrine triangulated the shape of the monophasic action 
potential as measured from the right atrium. These changes in restitution kinetics and 
monophasic action potential shape, in part, explain the tendency of LQT1 patients to develop 
torsade des pointes as a result of sympathetic stimulation.   
? Patients homozygous for the presumed more active ?1-adrenoceptor allele R389 had shorter 
QT-intervals at rest, during exercise and 24-hour ambulatory ECG recordings. Also, compound 
homozygosity for the two more active ?1-adrenergic polymorphisms R389 and S49 increased 
risk for symptomaticity.  
? The K897 KCNH2 channels exhibited slower deactivation and faster inactivation but showed 
a smaller degree of inactivation, changes expected to increase current during cardiac 
repolarization.  
? K897 channels showed a higher current density and more expression in mammalian cells 
than T897 channels. Corresponding with these changes, QT-intervals in LQT1 patients with 
the K897K genotype were shorter than in the group of patients with the K897T and T897T 
genotypes.
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